Phase 1 randomised, double-blind, placebo-controlled crossover study in 9 men using opioids recreationally: NYX-783 with oxycodone caused no severe or serious adverse events (85% mild) and no harmful cardiovascular or respiratory interactions; preliminary results.
RCTn = 9
Harvanek et al. Safety, tolerability, and drug-drug interactions of NYX-783 and oxycodone in persons using opioids recreationally: Preliminary results from a randomized, double-blind, placebo-controlled phase 1 study